Advertisement

Topics

Levosimendan in High Risk Heart Valve Surgery

2014-08-27 03:51:34 | BioPortfolio

Summary

Prospective, randomized, double blind study investigating the efficacy of levosimendan in heart failure after cardiac surgery.

Study hypothesis: Levosimendan diminishes the need for adrenergic inotropic drugs and morbidity and may improve survival after heart valve surgery.

Description

200 patients are prospectively randomized in a double blind study investigating the efficacy of levosimendan in heart failure after cardiac surgery. Levosimendan/placebo is administered as 24 hour continuous infusion beginning after anesthesia induction. Primary endpoint being adrenergic inotrope need after cardiopulmonary bypass and secondary endpoints hospital and 6-month mortality and major organ failure.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Conditions

Heart Failure

Intervention

levosimendan, placebo

Location

Kuopio University Hospital
Kuopio
Finland
70210

Status

Completed

Source

Kuopio University Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:51:34-0400

Clinical Trials [2442 Associated Clinical Trials listed on BioPortfolio]

Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure

Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design. Mo...

Levosimendan Pharmacokinetics in Children

Levosimendan is a drug used in patients with heart failure and has several advantages over other heart failure drugs. A lot of research has been done with Levosimendan in Adults, and the w...

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.

Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery

The purpose of this study protocol is to evaluate the blood concentrations of levosimendan when administered at different doses clinically employed during cardiopulmonary bypass or cardiac...

Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure

Purpose: This study evaluates the subacute effect of levosimendan infusion on exercise capacity and exercise hemodynamics compared with placebo in patients with advanced chronic heart fail...

PubMed Articles [7412 Associated PubMed Articles listed on BioPortfolio]

Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis.

Acute decompensated heart failure (ADHF) is associated with high morbidity and mortality. Intravenous inotropic agents play an important role in treating ADHF. Relatively small clinical studies have e...

EXPRESS: Levosimendan in Pulmonary Hypertension and Right Heart Failure.

Levosimendan in Cardiac Surgery: Evaluating the Evidence.

Levosimendan, a calcium-sensitizing and Adenosine triphosphate-sensitive potassium channel opening inodilator, has the potential to improve cardiac function without increasing oxygen consumption. The ...

The Reversible Covalent Reaction of Levosimendan with Cardiac Troponin-C in vitro and in situ.

The development of calcium sensitizers for the treatment of systolic heart failure presents difficulties including judging the optimal efficacy and the specificity to target cardiac muscle. The thin f...

Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.

The authors conducted a systematic review and network meta-analysis of placebo-controlled, randomized clinical trials in the post-Food and Drug Administration (FDA) guidance era to formally compare th...

Medical and Biotech [MESH] Definitions

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

More From BioPortfolio on "Levosimendan in High Risk Heart Valve Surgery"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...


Searches Linking to this Trial